Miraqules, a biotechnology company based in Bengaluru, will showcase its groundbreaking blood clotting technology at TechCrunch Disrupt 2025 in San Francisco from October 27 to 29. Co-founder and CEO Sabir Hossain developed this innovative solution after a personal experience motivated him to create a product that could save lives. The technology, which utilizes a nanotechnology powder that mimics blood clotting proteins, has the potential to transform trauma care.
The blood clotting powder acts rapidly, forming fibrous compounds at room temperature that effectively absorb blood when applied. “This is a product that will give you feedback instantly,” Hossain explained. “If there is a person bleeding, you apply it, and the bleeding stops. This whole thing happens within one or two minutes.” The company has already garnered attention as a Top 20 Startup Battlefield finalist, highlighting its significant potential in the healthcare sector.
Hossain’s journey into the world of biotechnology began during his graduate studies in biomedical engineering. While working in a research lab, he struggled to replicate the work of a doctorate student focused on creating 3D structures for bone tissue growth. “I was really bad at that, actually,” he admitted. Hossain faced challenges synthesizing materials, which often disassembled instead of forming the desired structures.
A turning point occurred when he ground the dismantled particles into a powder and introduced it to a team working on blood clotting solutions. The results were astonishing, as the powder clotted blood within five to ten seconds. “I rushed to my professor, and from there we started to think about what made it happen,” Hossain said. This led to the development of a novel process that combines off-the-shelf materials into a nanomaterial that effectively mimics blood clotting proteins.
Hossain and his childhood friend, Mubeen Midda, began working on bringing this technology to market with limited funding. Their efforts have not gone unnoticed; Miraqules has secured 11 patents across seven countries, including India, the United States, and Israel. The technology is currently being piloted in a trauma care center in India, with expectations for regulatory clearance in the country within the next few months. Additionally, the company aims to obtain clearance from the U.S. Food and Drug Administration by 2026.
From the outset, Miraqules sought guidance from the FDA through a pre-submission process, which provided valuable insights into the requirements for product approval. This proactive approach has been instrumental in navigating the regulatory landscape. Remarkably, the company has achieved these milestones with less than $700,000 in capital raised, primarily through grants.
As Miraqules looks to the future, it is eager to ramp up its deployment and pilot programs. The company has already received interest from ten different hospital chains in India and the Israeli Defense Forces, indicating strong market potential. For those interested in learning more about Miraqules and witnessing additional innovative pitches, TechCrunch Disrupt 2025 promises to be a vital event for networking and inspiration in the startup ecosystem.
Attendees can expect to engage with over 250 industry leaders and explore more than 300 showcasing startups across various sectors. This year’s Disrupt aims to provide insights that will sharpen business strategies and foster growth in the competitive landscape.
